Fibroblasts in fibrosis: novel roles and mediators

Ryan T. Kendall and Carol A. Feghali-Bostwick *
Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA

INTRODUCTION
Fibroblasts are the workhorse of the most important tissue that holds the human body together—connective tissue. Connective tissue joins and supports all other tissues, including the parenchymal tissues of organs. This connective tissue is made of fibroblasts widely-spaced in a vast extracellular matrix (ECM) of fibrous proteins and gelatinous ground substance. Fibroblasts produce the ECM’s structural proteins (e.g., fibrous collagen and elastin), adhesive proteins (e.g., laminin and fibronectin), and ground substance (e.g., glycosaminoglycans and glycoproteins). However, fibroblasts also play various additional roles beyond ECM production. For example, fibroblasts serve pivotal roles in ECM maintenance and reabsorption, wound healing, inflammation, angiogenesis, cancer progression, and in physiological as well as pathological tissue fibrosis. Ancillary to these various biological roles, fibroblasts produce and respond to a broad array of paracrine and autocrine signals, such as cytokines and growth factors. Targeting these ancillary signaling events is the main strategy underlying multiple lines of research for a new generation of treatments for fibroblast-related disorders.

Fibroblasts are mesenchymal cells derived from the embryonic mesoderm tissue, and they are not terminally differentiated. They can be activated by a variety of chemical signals that promote proliferation and cellular differentiation to form myofibroblasts with an up-regulated rate of matrix production. Fibroblast activation plays a vital role in wound healing however, in some cases and for reasons that remain to be fully elucidated, their activation becomes uncontrolled, producing a pathological fibrotic response that promotes multiple diseases and affects a variety of organs. Indeed, fibrosis plays a significant contributory role in most cases of organ failure. Examples are wide ranging: systemic sclerosis (SSc); idiopathic pulmonary fibrosis (IPF); liver cirrhosis; kidney fibrosis; and the cardiac fibrosis observed in cardiac hypertrophy resulting in heart failure. The essential role of fibroblasts in lung fibrosis was validated using lineage-specific deletion of the type II TGFβ receptor (Hoyles et al., 2011).

Here we review a variety of fibroblast functions that illustrate a central role for fibroblasts in the pathology of fibrosis. We review ECM production in relation to fibrosis, some examples of critical chemical signaling, myofibroblast differentiation, the role of fibroblasts in stromal-cancer interactions, and potential clinical therapies targeting fibroblasts.

FIBROBLAST ROLE IN MATRIX PRODUCTION AND MAINTENANCE
Fibroblasts’ most well-known biological role is the production of the rich ECM of connective tissues. Fibroblasts produce and secrete all components of the ECM, including the structural proteins, adhesive proteins, and a space-filling ground substance composed of glycosaminoglycans and proteoglycans.

STRUCTURAL PROTEINS
Fibroblasts produce an interconnecting meshwork of extracellular protein fibers and connector proteins that provide structure to tissue. Reciprocally, these proteins can promote the differentiation of profibrotic myofibroblasts through positive feedback
regulation during fibrosis (Blaauboer et al., 2013). The variety of ECM structures serve roles as diverse as forming lamina that delineate borders separating distinct cell types with different functions, to serving as interstitial regions that connect cells of a common type with a common biological function. Fibroblasts provide these specialized ECMs in different tissues by expressing and secreting a robust and variable repertoire of structural proteins with distinct properties. For example, the fibril rigidity provided by collagen type I, the most abundant protein in mammals, is due to its rope-shaped, triple-stranded helical tertiary protein structure that reinforces its tensile strength, preventing overstretching. In contrast, elastin proteins form highly crosslinked, yet unstructured, elastic networks that allow for expansive stretching without breaking. Tissues requiring differing degrees of rigidity vs. flexibility, such as skin and lung, differ in the relative expression of collagen subtype and elastin proteins. Moreover, the pathological histology of fibrosis includes an increase in the relative balance of collagen (Gilbane et al., 2013; McKleroy et al., 2013). A large number of genes that express different collagen subtypes also provide unique matrix properties. Fibroblast-mediated formation of basement membrane (composed of a layer of basal lamina and a layer of reticular lamina) serve as structural scaffolds critical for tissue regeneration in wound healing; cell barriers segregating epithelial from endothelial tissues; barriers preventing malignant escape or invasion of cancerous cells; filtration devices found in the glomerular filtration of blood in the kidney; and filtration of the alveoli-capillary interface in the lung. Basement membrane ECM is composed largely of collagen type IV, and in this environment, the presence of collagen type I promotes the up-regulation of TGFβ and epithelial-to-mesenchymal transdifferentiation (EMT), producing, for example, fibroblasts with a profibrotic phenotype in kidney fibrosis (Zeisberg et al., 2001).

ADHESIVE PROTEINS
Adhesive ECM proteins such as fibronectin and laminin form the connection between cells and the ECM. Fibronectins bind to ECM fibers and contain RGD domains required for interacting with the integrin transmembrane cell adhesion proteins. It is ironic that fibronectin is essential for collagen assembly into ECM, yet a conditional knock out of fibronectin expression in the liver was found to increase collagen production, TGFβ signaling, and hepatic fibrosis (Kawelke et al., 2011). Therefore, locally produced fibronectin in ECM also regulates the amount of active TGFβ and serves to protect tissue from TGFβ hyperstimulation (Kawelke et al., 2011). Laminins also interact with integrin receptors to regulate cell attachment to the basal lamina. In fact, laminin has been proposed as a biomarker for hepatic fibrosis (Santos et al., 2005).

GROUND SUBSTANCE
The ground substance of ECM is a hydrated gel of proteoglycans that is interspersed among the structural proteins. The ground substance forms a final pathway for nutrient flow beyond the reach of blood vessel transport into tissues as well as a pathway for intercellular communication. This cell-free medium forms an avenue for cell migration of immune cells, fibroblasts, and myofibroblasts. It is also an essential avenue for endothelial cell migration during angiogenesis. The proteoglycans of ground substance are proteins that are posttranslationally modified by the addition of unbranched polysaccharides called glycosaminoglycans (GAGs), or descriptively as mucopolysaccharides. These GAGs are composed of repeating disaccharide units that contain an amino sugar of either N-acetylgalactosamine or N-acetylgalactosamine and are often sulphated. The family of GAG posttranslational modifications found in ECM includes hyaluronan (non-sulfated), heparin and heparan sulfate, chondroitin and dermatan sulfate, and keratan sulfate.

Proteoglycans directly interact with many chemical signals, such as growth factors and TGFβ. Through these interactions, the ECM proteoglycans can regulate chemical signaling by either inhibiting or augmenting a signal’s responsiveness. The proteoglycan tenascin-C (TN-C) interacts with ECM (Chung et al., 1995), cell surface receptors (Schnapp et al., 1995; Midwood et al., 2009; De Laporte et al., 2013), and is secreted in response to TGFβ stimulation (Pearson et al., 1988). TN-C is highly expressed during embryonic development, chronic inflammation, and fibrosis. Our group has characterized the role of insulin-like growth factor binding protein (IGFBP)-3, which is overexpressed in fibrotic skin and lungs, in mediating the induction of TN-C by TGFβ (Brissett et al., 2012). Exposure of lung fibroblasts in vitro to IGFBP-3 directly induces TN-C production and secretion. Further, SSc patients with pulmonary fibrosis have significantly higher levels of circulating TN-C compared with SSc patients without pulmonary fibrosis (Brissett et al., 2012). Another ECM proteoglycan, decorin, antagonizes TGFβ activity (Yamaguchi et al., 1990). Decorin is a small proteoglycan that contains a single GAG chain of either chondroitin sulfate or dermatan sulfate. Decorin directly interacts with TGFβ and inhibits its profibrotic biological activity. Recombinant expression of decorin in the lung airways of mice inhibits bleomycin-induced pulmonary fibrosis (Kolb et al., 2001). In addition to the secreted proteoglycans of the ECM, there are also a number of cell membrane proteoglycans that can interact with chemical signals and function as co-receptors. An important example is the syndecans. Syndecan 2 (SDC2) is over-expressed during fibrosis and is induced in fibroblasts in response to both TGFβ and IGFBP-3 (Ruiz et al., 2012). Similar to the above examples, proteoglycans can also interact with membrane-bound and secreted proteases such as MMP-7 (Yu and Woessner, 2000) as well as secreted protease inhibitors such as TIMP-3 (Yu et al., 2000), regulating their biological activities in signaling and ECM processing.

ECM MAINTENANCE AND REABSORPTION
In addition to extracellular matrix production, fibroblasts are also responsible for its maintenance and reabsorption. Unlike bone, where a specialized cell type, osteoblasts, produces bone (a highly mineralized extracellular matrix) and a distinct cell type, osteoclasts, reabsors bone, there are no known fibroblast cells that specialize in matrix reabsorption. As far as we know, the same fibroblasts that produce ECM are responsible for matrix maintenance and degradation. As such, these cells have important roles in resolving pathological fibrosis. Collagen
maturation is controlled by the enzyme lysyl oxidase (Lox), which is produced by fibroblasts, cross-links collagen fibers, and thereby strengthens ECM. Interestingly, inhibiting LOX-mediated collagen cross-linking antagonizes both fibrosis and tumor metastasis (Cox et al., 2013). Collagen turnover (catabolism) is regulated by a multitude of secreted extracellular proteases. Fibroblasts produce both matrix degrading enzymes (such as metalloproteinases, aka MMPs) as well as their inhibitors (the tissue inhibitors of metalloproteinases, aka TIMPs). Curiously, MMP expression in IPF is increased, and experiments with various MMP knock-out mice demonstrate protection from bleomycin-induced lung fibrosis (McKleroy et al., 2013).

CONCOMITANT AND INTERWOVEN BIOLOGICAL ROLES OF FIBROBLASTS

WOUND HEALING

Fibroblasts have a pivotal role in wound healing in response to tissue injury. First and foremost, fibroblasts respond to wound healing by proliferating and by chemotaxing to the sites of tissue injury to rebuild the ECM as a scaffold for tissue regeneration. Fibroblast to myofibroblast transitioning enables the contraction of the matrix to seal an open wound in the event of the loss of tissue (Gabbiani, 2003; Midwood et al., 2004). Fibroblasts also play a role in blood clotting, such as in the production of urokinase plasminogen activators (PAs) and their inhibitors (PAlS). Fibroblasts express the protease activated receptor PAR1 that enables fibroblast responsiveness to activated thrombin. PAR1 receptor expression is upregulated in IPF (Howell et al., 2005) and in lung tissue of SSc patients (Bogatkevich et al., 2005). Further, PAR1 knockout mice resist bleomycin-induced lung fibrosis (Howell et al., 2005). PAR1 receptors have well documented roles in the process of fibrosis, and PAR1 receptor antagonists as well as thrombin inhibitors could be beneficial for treating SSc and IPF (Atanelishvili et al., 2014).

INFLAMMATION

Fibroblasts serve roles in inflammation and immune cell recruitment to sites of tissue injury. Furthermore, fibroblasts produce and are responsive to many inflammatory cytokines. Fibroblasts are responsive to cytokines such as TGFβ1, IL-1β, interleukin-6 (IL-6), IL-13, IL-33 (Feghali and Wright, 1997; Scotton and Chambers, 2007; Savinko et al., 2012), as well as prostaglandins (Keerthisingam et al., 2001; Stratton et al., 2002; Maher et al., 2010) and leukotrienes (Mensing and Czarnetzki, 1984; Chibana et al., 2003; Eap et al., 2012). Fibroblasts are stimulated chemically by inflammatory agents to differentiate into myofibroblasts that have a greatly up-regulated rate of matrix production (discussed in more detail below). In turn, fibroblasts produce and secrete cytokines such as TGFβ1, IL-1β, IL-33, CXC, and CC chemokines (Feghali and Wright, 1997; Gharaee-Kermani et al., 2003, 2012; Scotton and Chambers, 2007), as well as reactive oxygen species (Amara et al., 2010; Bondi et al., 2010). These factors allow fibroblasts to assist in the activation and migration of resident immune cells such as macrophages. Moreover, the recruitment of non-resident immune cells is facilitated by the fibroblast-mediated production and maintenance of the relatively spacious, non-solid ground substance of the extracellular matrix, which plays an important role as a thoroughfare for the extravasation of immune cells into connective tissue. These tools endow fibroblast roles in chemical (non-specific) and cell-mediated immunity, acute and chronic inflammation, and inflammation resolution. Fibroblasts can contribute to chronic inflammation (Flavell et al., 2008), and reciprocally, inflammatory cytokines promote fibroblast to myofibroblast transition, facilitating fibrosis.

ANGIOGENESIS

Fibroblasts have close interactions with endothelial cells and facilitate angiogenesis into tissues beyond the reach of existing blood vessels. This response requires the migration of endothelial cells to construct tubes through the ground substance of connective tissue (Dunn et al., 2000). Fibroblasts play a critical role in angiogenesis; fibroblast-derived matrix proteins and cytokines are essential for endothelial cell-mediated lumen formation (Newman et al., 2011). A major mechanism for this phenomenon is the fibroblast-mediated production and release of vascular endothelial growth factor (VEGF), which acts on VEGF receptors expressed on endothelial cells to promote angiogenesis. Interestingly, dermal fibroblasts from SSc patients overexpress VEGF in response to autocrine TGFβ signaling (Kajihara et al., 2013). This VEGF could play a role in the vascular damage that in turn promotes fibroblast activation, thereby supporting fibrosis (Kajihara et al., 2013).

ANCILLARY SIGNALING FUNCTIONS OF FIBROBLASTS

The signaling factors associated with fibroblast biology are not necessarily specific for one biological role over another. Below we discuss these signaling factors with respect to their sources and their cellular targets (Figure 1). The net effect of multiple stimuli that recapitulate the milieu in human tissues is difficult to reproduce in the laboratory, although initial efforts using ex vivo organ cultures such as skin (Yasuoka et al., 2008; Yamaguchi et al., 2012) are promising.

PARACRINE SIGNALS THAT ACT ON FIBROBLASTS

Some factors act to promote a probiotic phenotype. Platelet-derived growth factor (PDGF) (Scotton and Chambers, 2007), IL-6 (Feghali et al., 1992), IL-13 (Fuschiotti, 2011; Fuschiotti et al., 2013), and the eicosanoid leukotrienes (Mensing and Czarnetzki, 1984; Chibana et al., 2003; Eap et al., 2012) are cytokines that promote inflammation and the development of a fibrotic response. PDGF is produced by a variety of cell types, such as platelets, endothelial cells, smooth muscle cells, and macrophages. It acts on the mesenchyme and fibroblasts to induce proliferation, differentiation, and ECM production (Scotton and Chambers, 2007). PDGF is important for wound healing, inflammation, angiogenesis, embryonic development, and fibrosis. IL-6 is a pro-inflammatory cytokine that acts on a range of cell types and is produced by T cells, macrophages, skeletal muscle cells, and fibroblasts (Feghali and Wright, 1997). IL-6 has well-known roles in inflammation, cellular differentiation, and fibrosis. IL-6 is elevated in the blood of SSc patients and produced in excess by SSc fibroblasts (Feghali et al., 1992; Feghali and Wright, 1997). Elevated IL-6 levels correlate with worse long-term survival, and therefore IL-6 could potentially be used as a prognostic clinical
biomarker for patients with diseases such as SSc (Khan et al., 2012). IL-13 is a cytokine mainly produced by mast cells but also T lymphocytes (Wynn, 2003), and it acts on multiple cell types, including fibroblasts. With roles in both inflammation and fibrosis, IL-13 can stimulate TGFβ production, TGFβ activation, collagen production, MMP expression, fibroblast proliferation, and myofibroblast differentiation (Fuschiotti, 2011; Fuschiotti et al., 2013). The leukotriene eicosanoids are additional signals that induce fibroblast proliferation and matrix production contributing to fibrosis (Mensing and Czarnetzki, 1984; Chibana et al., 2003; Eap et al., 2012).

Of special note, the fibroblast growth factor (FGF) family of genetically related protein ligands was originally identified as mitogens and differentiation factors for fibroblasts (Armelin, 1973; Gospodarowicz, 1974). Despite the fact that this family has since been found to act on multiple cell types, FGFs require heparin or heparan sulfate proteoglycan molecules to bind their surface receptors (Ornitz and Itoh, 2001). Therefore, they require close proximity to ECM and the fibroblasts that secrete ECM. There are 22 FGF genes found in humans (Ornitz and Itoh, 2001), and these genes are alternatively-spliced (Ornitz and Itoh, 2001) generating additional FGF proteins. FGF ligands activate a family of 4 FGF receptors with differing specificities (Dionne et al., 1991). High amounts of active FGF2 are found in bronchoalveolar lavage fluid and in lung tissues of patients with pulmonary fibrosis (Henke et al., 1991; Inoue et al., 1996). Mast cell-generated FGF2 is a profibrotic factor implicated in SSc and IPF (Veraldi and Feghali-Bostwick, 2012).

Paracrine factors that can antagonize fibrosis have also been described. The eicosanoids prostaglandin E2 (PGE2) (Keerthisingam et al., 2001; Maher et al., 2010) and prostacyclin (PGI2) (Stratton et al., 2002) are two examples of paracrine signals that inhibit the fibrotic response. PGE2 inhibits fibroblast proliferation and collagen production (McAnulty et al., 1997; Goldstein and Polgar, 1982; Saltzman et al., 1982). It acts on target cells by activating the G protein-coupled EP receptors 1–4. PGE2 has been observed to inhibit fibroblast to myofibroblast differentiation and the TGFβ1 stimulated expression of α smooth muscle actin (αSMA) in lung fibroblasts via the EP2 subtype receptors (Kolodsick et al., 2003). PGE2 also has an anti-apoptotic effect on the alveolar epithelium (Maher et al., 2010). Iloprost is a synthetic analog of prostacyclin eicosanoid PGI2 that dilates systemic and pulmonary arterial vascular beds and is used for the treatment of patients with SSc (Erre and Passiu, 2009).

PARACRINE SIGNALS PRODUCED AND BROADCAST BY FIBROBLASTS

IGFBP-3 and -5, IGF-II, connective tissue growth factor (CTGF), IL-33, CXC chemokines, CC chemokines, and reactive oxygen species (ROS) are paracrine signals produced by fibroblasts that further enhance a tissue fibrotic response. Both IGFBP-3 and -5 are profibrotic factors implicated in SSc and IPF (Veraldi et al., 2009; Veraldi and Feghali-Bostwick, 2012). CTGF plays pivotal roles in wound healing, angiogenesis, and fibrosis. It is highly expressed by endothelial cells in response to a variety of stressors, but it is also expressed and released by fibroblasts. CTGF interacts with a wide variety of receptors, extracellular ligands, as well as ECM proteins (Liu et al., 2011a). CTGF knock-out mice are less responsive to the induction of fibrotic skin lesions by bleomycin (Liu et al., 2011a). Conversely, transgenic mice with fibroblast-specific expression of CTGF develop fibrosis without any other profibrotic stimulus and display an accelerated fibrotic response relative to exogenously added CTGF (Sonnynal...
et al., 2010). CTGF is well-characterized to act synergistically with TGFβ to promote pathological fibrosis. Furthermore, TGFβ1 induces CTGF in fibroblasts (Leof et al., 1986; Paulsson et al., 1987; Soma and Grotendorst, 1989; Igarashi et al., 1993; Mori et al., 1999). IL-33 is a cytokine produced primarily by endothelial and smooth muscle cells in the vasculature and the lungs. However, its production by dermal fibroblasts can also be induced by inflammation and in cardiac fibroblasts by mechanical stress. Knocking down IL-33 expression in mice is cardioprotective in the face of chronic angiotensin II stimulation (Sanada et al., 2007). IL-33 facilitates inflammation and fibrosis (Savinko et al., 2012). CXC and CC chemokines are broadcast by fibroblasts and play significant roles in the chemotaxis of various leukocytes to sites of tissue injury (Gharaei-Kermani et al., 2003, 2012). TGFβ also induces NADPH oxidase 4 (NOX4) in fibroblasts (Amara et al., 2010; Bondi et al., 2010), implicating reactive oxygen species (ROS) and oxidative stress in the pathology of fibrosis. NOX4 generates a basal level of extracellular H2O2. NOX4 mRNA expression is increased in rat kidney fibroblasts in culture (Bondi et al., 2010) and in primary lung fibroblasts derived from the lungs of patients with IPF (Amara et al., 2010).

Fibroblasts do not typically express and release the angiotensin II (AngII), however both activated macrophages and myofibroblasts produce AngII during the pathology of fibrosis (Berk et al., 2007). Although the phenomenon is not well characterized in most tissues, AngII is known to promote TGFβ-mediated cardiac remodeling (Rosenkranz, 2004) and the fibrosis observed in left ventricular cardiac hypertrophy (Rosenkranz, 2004). These findings suggest that AngII could contribute to fibrosis in other tissues.

**AUTOCRINE ACTIONS AMONG FIBROBLASTS**

TGFβ (Scotton and Chambers, 2007), IL-1β, and IL-6 (Feghali and Wright, 1997) are examples of cytokines that are both produced by fibroblasts (as well as other cell types) and that act on fibroblasts to promote inflammatory and fibrotic responses. TGFβs are named after their ability to act on fibroblasts to induce oncogenic transformation. The three known TGFβ ligands assert their biological actions by activating TGFβ receptors, cell surface serine/threonine kinase receptors. TGFβ is the prototypic profibrotic cytokine. It acts on fibroblasts and myofibroblasts to promote proliferation, migration, matrix production, the production of chemotactic signals promoting leukocyte recruitment to the site of injury, fibrosis, and the differentiation of fibroblasts to myofibroblasts. Inhibitors of each TGFβ receptor antagonize fibrosis development in experimental models (Bonnaud et al., 2005; Fu et al., 2011). The cytokine IL-1β’s expression and release is induced by a wide variety of cells, including fibroblasts, in response to inflammation (Feghali and Wright, 1997). IL-1β is a potent pro-inflammatory cytokine that also induces production of the profibrotic cytokines PDGF and TGFβ.

Some autocrine fibroblast factors counteract fibrosis, such as the hepatocyte growth factor (HGF). HGF is a protein produced by fibroblasts and acts by binding the receptor tyrosine kinase c-Met expressed on nearby epithelial cells, endothelial cells, and fibroblasts (Bogatkevich et al., 2007a,b; Crestani et al., 2012). HGF also plays an important role in wound healing, angiogenesis, and tumorigenesis.

**SOURCES OF FIBROBLASTS**

Fibroblasts are a heterogeneous cell population that consists of subsets with different capacities to produce ECM components such as collagen. Fibroblast subpopulations have been described in the skin (Jelaska and Korn, 2000) and lung (Pechkovsky et al., 2010). Furthermore, fibroblast phenotypes may differ across sites of the same organ, as has been shown in skin. In fact, fibroblasts from different skin sites retain positional memory with distinct gene expression profiles (Chang et al., 2002). Furthermore, fibroblasts are chemotactic and can migrate and accumulate in new areas in response to secreted cytokines, a behavior well characterized in the wound healing response after tissue injury. Although the parenchyme of the liver, pancreas, and lung are derived from endothelial tissue and the parenchyme of the skin and brain are derived from epithelial tissue, the stromal connective tissue found in all organs is derived from mesothelial tissue. Yet, due to the differing mixture of neighboring tissue types, there is the potential for differential fibroblast phenotypes and differential fibrotic responses in each of these organs.

Fibroblasts are not a terminally differentiated cell type and retain the potential to be activated for differentiation into subtypes of fibroblast-like cells. Myofibroblasts are rarely found in healthy human physiology; they become vastly up-regulated after injury and play a critical role in the wound healing response (Gabbiani, 2003; Midwood et al., 2004). Myofibroblasts can originate from a variety of precursor cells, as shown in Figure 2. Major developmental signaling factors such as the Wnt (Liu et al., 2012), Notch (Kavian et al., 2012), and Sonic hedgehog ligands (Stewart et al., 2003; Ding et al., 2012) have well-described roles in myofibroblast differentiation from precursor cells. Myofibroblasts are well characterized to differentiate from resident fibroblasts in vivo and in vitro in response to profibrotic cytokine stimulation. However, myofibroblasts have also been observed to differentiate from various other precursor cells, including epithelial cells, endothelial cells, pericytes, multipotent monocytes, and fibrocytes. Whether different cell origins are the source of myofibroblasts in different tissues remains to be determined.

The myofibroblast phenotype is characterized as: (i) expressing αSMA; (ii) contractile; (iii) having a greater rate of ECM synthesis and secretion; and (iv) resistant to apoptosis. The contractile biology of myofibroblasts facilitates ECM fiber manipulation and wound contraction at sites of injury. Myofibroblasts display a heightened and constitutive expression of cytokines, chemokines, and cell surface receptors (Strehlow and Korn, 1998; Abraham and Varga, 2005). These differentiated myofibroblasts also display epigenetic changes (Wang et al., 2006a).

**EPITHELIAL CELLS**

The EMT has been observed as a source of myofibroblasts in kidney fibrosis (Ng et al., 1998; Jinde et al., 2001; Liu, 2004); however, subsequent attempts to trace such phenomena in the skin, lung, heart, and liver have been largely unsuccessful in vivo, suggesting that EMT-mediated formation of myofibroblasts is
FIGURE 2 | Myofibroblasts can differentiate from a variety of precursor cell types.

not substantial. Recent evidence argues against epithelial cells as the main source of myofibroblast differentiation in idiopathic lung fibrosis. Using lineage tracing with recombinant td-Tomato and e-GFP tags and confocal microscopy resolution, Rock et al. demonstrated focal accumulation of fibroblasts derived from the proliferation of stromal cells (Rock et al., 2011). Recent transgenic lineage tracing studies in mouse kidney also indicate that most myofibroblasts are not derived from epithelial cells (Lin et al., 2008; Humphreys et al., 2010). Although these studies using rodents contradict findings suggesting an epithelial origin to myofibroblasts, they do not exclude the possibility that EMT may occur in human tissues.

ENDOTHELIAL CELLS
Another source of myofibroblasts during fibrosis has been hypothesized to originate from endothelial cells by a process of endothelial-mesenchymal transition (EndoMT) (Piera-Velazquez et al., 2011). This event has been characterized in animal models of fibrosis; however, similar phenomena in human fibrosis patients have not yet been well characterized.

VASCULAR SMOOTH MUSCLE CELLS (VSMC)
The many similarities between myofibroblasts and VSMCs promote the question of a potential lineage relationship between the two cell types (Yoshida and Owens, 2005). For example, these cells are contractile and they share multiple markers such as αSMA, SM22α, desmin, and vimentin (Yoshida and Owens, 2005). Furthermore, myofibroblasts express proteins, such as osteopontin, that can be induced in VSMCs by phenotypic modulator ligands (Yoshida and Owens, 2005). However, the biological roles of these two cell types in disease are different (Gan et al., 2007). Furthermore, myofibroblasts and VSMCs have distinct transcriptional mechanisms for αSMA expression (Gan et al., 2007). Observations such as the induction of αSMA expression in myofibroblasts and the reduction in αSMA expression in VSMCs during vascular injury (Yoshida and Owens, 2005) suggest the reduction of a contractile phenotype in VSMCs could also promote another source of myofibroblasts differentiation.

PERICYTES
Pericytes are mesenchyme-derived cells that wrap around small blood vessel walls and closely associate with the outer surface of the endothelial cell layer. Pericytes regulate the permeability of the blood vessel wall; for example, pericytes are the principal cell type that regulates the permeability of the blood–brain barrier (Armulik et al., 2010). Pericytes physically interact with endothelial cells and chemically via paracrine signaling to control the tight junctions and transvessicular trafficking across endothelial cells. As such, malfunctioning pericytes can promote vascular leaking (Schrimpf et al., 2012), and the observation that pericytes can be induced to differentiate into myofibroblasts, losing their pericyte functionality, suggests that this differentiation may contribute to both tissue fibrosis and vascular leakage in IPF (Hung et al., 2013). Pericytes are not a terminally differentiated cell type; they can further differentiate into fibroblasts, osteoblasts, and smooth muscle cells. Pericytes endogenously express αSMA and have a functioning contractile apparatus; therefore, distinguishing between these cells and other cell types is challenging. One genetic fate mapping study investigating the potential contribution of pericytes in mice to bleomycin-induced lung fibrosis utilized the nerve/glial antigen 2 (NG2) protein, a chondroitin sulfate cell surface-associated proteoglycan, as a marker for this cell type. This strategy found...
no appreciable contribution of pericytes to the expansion of myofibroblasts and the resulting fibrosis even though the pericyte population itself did expand significantly (Rock et al., 2011). A different investigation utilized the forkhead transcription factor FoxD1 as a marker for lung pericytes and found that up to 68% of αSMA-expressing cells in fibrotic lungs are pericyte-derived (Hung et al., 2013). These studies suggest that multiple subpopulations of pericytes may exist in the lung and differentially contribute to myofibroblast formation and fibrosis.

**MONOCYTES AND FIBROCYTES**

Fibrocytes are circulating fibroblast-like cells in the vascular system that are derived from bone marrow stem cells (Bucala et al., 1994). “Fibrocyte” is a term sometimes ascribed to a relatively inactive fibroblast-like cell, whereas the term “fibroblast” designates a fully active cell as described throughout our review. Fibrocytes can extravasate from vessels into connective tissues. In the kidney, it has been proposed that myofibroblasts in fibrotic areas could be derived from bone marrow progenitor multipotent cells via a cellular differentiation lineage: bone marrow progenitor cell to monocyte to fibrocyte to fibroblast (Quan et al., 2004; Pilling and Gomer, 2012). Circulating CD14+ immunophenotypic monocytes derived from the plasma of SSC patients are reported to express greater αSMA (and so an increased maturation toward myofibroblasts) compared to those of healthy control individuals but with minor functional contraction properties as determined with a collagen contraction assay (Binaï et al., 2012). The blood of SSC patients with interstitial lung disease is enriched for fibrocytes and monocytes with an overt profibrotic phenotype (Mathai et al., 2010). However, lineage tracing studies in rodents display differing conclusions. GFP-expressing fibroblasts derived from the multipotent, transgenic bone marrow transplanted into chimeric normal mice appear to be a unique population of cells that do not express αSMA and fail to differentiate into myofibroblasts when extracted and stimulated ex vivo in culture (Hashimoto et al., 2004; Kisseleva et al., 2006; Barisic-Dujmovic et al., 2010; Rock et al., 2011). Similarly, using an αSMA promoter-driven GFP transgenic mouse, no kidney or bone marrow stromal expression was observed in chimeric wild-type mice (Yokota et al., 2006). However, the chimeric mice were only analyzed under physiologic conditions, and no profibrotic stimulus was tested in this model (Yokota et al., 2006). In contrast, in another study, bone marrow from GFP transgenic mice were transplanted into wild-type rats, and a 23% increase in the number of GFP and αSMA-expressing cells in the pancreas was observed to peak in the early stage of an experimentally-induced but clinically-relevant pancreatitis rat model (Mathai et al., 2010; Akita et al., 2012). In all, despite substantial evidence that activated myofibroblasts are derived from local stromal fibroblasts, blood borne monocytes and monocyte-derived cells appear to facilitate fibrosis via the production of ECM and paracrine signaling with resident profibrotic cells (Murray et al., 2012).

**ADVENTITIAL FIBROBLASTS IN PULMONARY HYPERTENSION**

A very similar role of fibroblast activation appears to promote pulmonary hypertension compounding other fibrotic disorders. Pulmonary hypertension can be a complication of IPF and SSC and is a significant contributor to mortality (Lee et al., 1992; Arcasoy et al., 2001; King et al., 2001). Adventitial fibroblasts found in blood vessels can be activated by hypoxia and are implicated as a source of myofibroblasts that promote vascular remodeling and the associated pulmonary hypertension (Stenmark et al., 2006).

**FIBROBLASTS IN CANCER BIOLOGY**

Fibroblasts have an integral role in cancer beyond sarcomas and cancers originating from fibroblastic cells. Non-cancerous fibroblasts interact with cancer cells, affecting tumor biology and pathogenesis. The biological processes of wound healing, inflammation, fibrosis, angio genesis, and their associated biochemical machinery all play critical roles in cancer by regulating the microenvironment of a tumor, tumor size, and tumor invasion of adjacent tissues and metastasis (Mueller and Fusenig, 2004). Fibroblasts in and around tumors are persistently activated by tumor cells (Kalluri and Zeisberg, 2006). In response, fibroblasts secrete cytokines and ECM that modulate tumor progression and regulate stroma-cancer interactions (Madar et al., 2013). Non-cancerous fibroblasts surrounding tumors contribute directly to angiogenesis and tumor growth by producing multifarious signaling molecules (Madar et al., 2013). Fibroblasts also secrete the ECM that modulates tumor progression, and fibroblasts remodel the connective tissue surrounding a tumor, allowing cancerous cells to be released from a contained tumor into the vascular system, thereby promoting metastasis (Li et al., 2011b). As such, fibroblast cells also participate in the pathogenesis of carcinomas—the more abundant cancers originating from epithelial cells. In spite of recent advances in delineating the role of fibroblasts in tumor progression, the role of these cells in earlier tumor development is still incompletely understood.

**POTENTIAL THERAPIES TARGETING FIBROBLASTS**

Since fibroblasts are a central effector cell in fibrosis, they are suitable therapeutic targets. There have been some recent exciting research findings inciting potential strategies to combat the pathological fibrotic response that occurs in various disorders. The examples listed below are not intended to be a comprehensive presentation for the pipeline of future antifibrotic therapies that target the fibroblast cell lineage. There are multiple strategies being investigated that are too numerous to cover here. The following examples help to illustrate the diverse range of targeting strategies where novel therapies potentially could ensue.

**ENDOSTATIN**

Endostatin is an endogenous inhibitor of angiogenesis that has completed clinical trials as an anticancer agent to prevent the growth of tumor mass. It inhibits endothelial cell proliferation and vessel formation (O’Reilly et al., 1997) but also acts on fibroblasts (Yamaguchi et al., 2012). Endostatin is a small peptide (20–30 KDa) derived from the carboxy terminus of the collagen type XVIII produced and released by fibroblasts. Endostatin is then released from this precursor protein by proteolytic cleavage by the action of cathepsin L (Felbor et al., 2000), and peptides of differing lengths have also been reported to be generated by the...
matrix metalloproteases MMP-3, -7, -9, -13, or -20 (Heljasvaara et al., 2005). Endostatin concentrations are greater in the blood and lungs of patients with IPF and SSc, but these concentrations do not seem to reach “therapeutic” levels (Hebbar et al., 2000; Sumi et al., 2005; Richter et al., 2009). Interestingly, the amino terminus portion of endostatin’s carboxy terminus contains the antifibrotic activity, suggesting that the two biological functions can be attributed to dissociable domains (Yamaguchi et al., 2012). Indeed, a 48 amino acid portion of endostatin’s carboxy terminus has strong antifibrotic actions in vitro, in vivo, and ex vivo in human tissue (Yamaguchi et al., 2012). This peptide ameliorates pulmonary and dermal fibrosis in an animal model and ex vivo in human skin in response to TGFβ (Yamaguchi et al., 2012).

**VITAMIN D3**

Vitamin D is important for regulating mineral absorption in the intestines, calcium, and phosphate concentrations in blood, and for maintaining bone integrity. However, vitamin D deficiency has also been found to correlate with many extra-osseous disorders. Vitamin D3 is processed by the liver to form the biologically active form 1,25-dihydroxyvitamin D3 (1,25-(OH)2 vitamin D3). 1,25-(OH)2 vitamin D3 activates the vitamin D receptor (VDR, a steroid hormone receptor) that heterodimerizes with retinoid hormone receptor to directly regulate gene transcription. 1,25-(OH)2 vitamin D3 inhibits the expression of type I collagen in hepatic stellate cells (Potter et al., 2013). Furthermore, 1,25-(OH)2 vitamin D3 has been observed to inhibit a fibrotic response in human primary lung fibroblasts (Ramirez et al., 2010), and 1,25-(OH)2 vitamin D3 deficiency correlates with the severity of liver fibrosis and that of SSc (Vacca et al., 2009; Caramaschi et al., 2010; Rios Fernandez et al., 2010; Arnsø et al., 2011; Slominski et al., 2013). These studies suggest that the correction of vitamin D deficiency is promising as a clinical strategy to alleviate fibrotic disorders.

**EPIGENETICS**

Epigenetic changes in fibrosis are the subject of active investigation. Several epigenetic modifications, like histone posttranslational modifications and DNA methylation events, have been reported. The fact that these epigenetic modifications do not alter the DNA sequence suggests they are reversible, and as such, they represent an attractive therapeutic strategy for countering fibrosis. Cylooxygenase 2 (COX2) expression—a biosynthetic enzyme for antiinflammatory prostaglandin production—is suppressed in IPF due to decreased histone acetylation (Coward et al., 2009), and histone deacetylase 4 (HDAC4) activity mediates TGFβ-stimulated myofibroblast differentiation in a response that can be inhibited by global inhibition of HDACs (Glenisson et al., 2007). HDAC7 has been proposed as a potential target for the treatment of SSc (Hemmatazad et al., 2009). DNA methylation of the gene FLI1 coding for the ETS transcription factor FlI-1 inhibits its genetic expression, resulting in enhanced collagen type I expression and persistent activation of fibroblasts in SSc (Wang et al., 2006a). Primary fibroblasts isolated from the adventitial layer of blood vessels following vascular injury maintain their activated, profibrotic state when grown in vitro (Li et al., 2011). The constitutive activation is an imprinted phenotype maintained by epigenetic alterations in key inflammatory and pro-fibrotic genes (Li et al., 2011). Epigenetic drugs have been approved for cancer, paving the way for using such agents, including DNA demethylating agents, for other diseases. The reversibility of epigenetic alterations and the ready availability of small molecule inhibitors of these enzymes provide a potential future therapeutic strategy that could antagonize the profibrotic phenotype of fibroblasts.

**WNT-LIKE SIGNAL TRANSDUCTION PATHWAY**

Wnt signaling and a classical Wnt-like intracellular signal transduction pathway in fibrosis are a bustling area of research, and multiple proteins within this pathway have been proposed as druggable targets to prevent myofibroblast differentiation and fibrosis. Wnt is a paradigm developmental signaling protein that regulates proliferation, migration, and cell fate determination. Wnt ligands activate frizzled receptors—members of the G protein-coupled receptor (GPCR) superfamily of proteins that share common structure and function relationships—and promote the inhibition of glycogen synthase kinase β3 (GSKβ3). Interestingly, many other GPCRs such as the lysophosphatidic acid receptor, the angiotensin type I receptor, the endothelin 1 receptor, and CC and CXC chemokine receptors regulate myofibroblast differentiation and fibrosis. GPCRs have also been demonstrated to couple to the Wnt-like intracellular signal transduction cascade Akt-GSKβ3-β-catenin-PPARγ (Beaulieu et al., 2004, 2005; Glenisson et al., 2011). However, it is not yet known if this cascade is the main contributor for GPCR-regulation of myofibroblast transition and fibrosis. Regardless, it is an interesting observation that multiple targets belonging to this signaling pathway are currently being actively investigated as potential targets for fibrosis therapies.

There is an apparent activation of the developmental Wnt-β-catenin program in SSc (Bhattacharyya et al., 2012). Wnt activated β-catenin promotes fibroblast to myofibroblast transition in human skin (Liu et al., 2012) and is required for TGFβ-mediated fibrosis (Akhtemshina et al., 2012). While Akt is not required for Wnt-stimulated β-catenin accumulation (Torres et al., 1999; Chen et al., 2000), Akt has been implicated in sustaining the Wnt signaling cascade (Fukumoto et al., 2001). Akt is a critical node of PI3K signaling and regulates cell cycle, cell growth, and cell fate determination. PI3K-Akt signaling is also utilized as a non-canonical pathway of TGF receptors that contribute to fibrosis (Wan et al., 2013). Sustained Akt activation is critical for upregulating αSMA expression and myofibroblast differentiation in the wound healing response, implicating Akt as a potential therapeutic target for fibrosis. Whereas a constitutively active Akt1 protein (myr-Akt1) induces αSMA expression in fibroblasts, a dominant negative Akt1 (Akt1 K179M) inhibits αSMA expression (Abdalla et al., 2013). Akt is a ubiquitous kinase that phosphorylates and inactivates the constitutive activity of GSKβ3 (Fang et al., 2000). Knocking out GSKβ3 expression in fibroblasts accelerates wound healing, increases fibrosis, enhances collagen production, decreases cell apoptosis in wound sections, increases profibrotic αSMA expression, and increases myofibroblast formation (Kapoor et al., 2008). The transcriptional coregulator
β-catenin is required for the TGFβ-mediated inhibition of peroxisome proliferator-activated receptor γ (PPARγ) expression in hepatic stellate cells (Qian et al., 2012). PPARγ is a nuclear receptor that is important for mesodermal cell fate determination. PPARγ expression and activity promotes adipocyte differentiation and inhibits fibroblast and hepatic stellate cell activation of the profibrotic phenotype (Qian et al., 2012). PPARγ agonists inhibit lung myofibroblast proliferation in vivo as well as TGFβ-mediated myofibroblast differentiation and collagen production in culture (Milam et al., 2008). PPARγ agonists also inhibit dermal fibrosis (Wei et al., 2010, 2012). Although only an associative depiction of a pathway is characterized here from research on individual proteins in this pathway, collectively they suggest that a Wnt-like pathway could have a strong influence on myofibroblast differentiation and fibrosis.

**Fibroblast Receptors**

Caveolin 1 inhibits the function of the chemotactic receptor CXCR4 in fibrocytes (Tourkina et al., 2011) and caveolin 1 is down regulated in IPF (Wang et al., 2006b). The introduction of a peptide containing the caveolin scaffolding domain of caveolin 1 is sufficient to inhibit fibrocyte accumulation in the lungs in a bleomycin-induced animal model of fibrosis, suggesting that the caveolin scaffolding domain could be employed as a potential therapy for SSc lung disease (Tourkina et al., 2011). In yet another example, the single nucleotide polymorphism L412F in the gene expressing Toll-like receptor 3 in pulmonary fibroblasts has been found to correlate with a greater risk of mortality in IPF patients (O’Dwyer et al., 2013). The L412F polymorphism could be used as a biomarker for more progressive fibrotic disease, and the resulting loss of function of TLR3 is a potential therapeutic target in IPF (O’Dwyer et al., 2013). This study highlights the importance of personalized medicine approach to the multifactorial group of fibrotic disorders. The inhibition of TLR4 has been reported to antagonize AngII-induced cardiac fibrosis (Wang et al., 2014), the activity of TLR4 in hepatic stellate cells enhances liver fibrosis (Seki et al., 2007), and the activity of TLR4 in skin fibroblasts enhances Scs (Bhattacharyya et al., 2013). Here, the entanglement of inflammatory and ECM-producing functions of fibroblasts can be exploited to improve fibrotic therapies (Bhattacharyya et al., 2013).

Given the multifactorial etiology of various fibrotic disorders, both in different tissues and within the same tissue (Murray et al., 2012), the increasing interest in developing and employing personalized medicine, where a one-size-fits-all approach is unlikely to be as effective, offers to accelerate the development of more effective antifibrotic therapies for defined subsets of patients.

**Summary**

Fibrosis is the thickening of ECM that is preceded by inflammation or physical tissue injury. Fibroblasts are the principal cell type that produces, maintains, and reabsorbs ECM. These fibroblasts have the capacity to become activated by inflammatory cytokines to myofibroblasts that display up-regulated cellular migration, exaggerated ECM production, the endowment of a contractile apparatus, and increased chemical signaling secretion and responsiveness. Although various precursor cell types have been observed to contribute to myofibroblast development, resident fibroblast stromal cells appear to be the most significant contributing source of myofibroblasts and the resulting tissue fibrotic response in diseases such as SSC and IPF. Thus, fibroblasts are a suitable therapeutic target. In view of the numerous factors at play in fibrosis, it is likely that combinatorial therapy that includes targeting fibroblasts will be more effective than single target approaches for the treatment of organ fibrosis.

**Acknowledgment**

Supported by K24 AR060297.

**References**

Abdalla, M., Goc, A., Segar, L., and Somanath, P. R. (2013). Akt1 mediates alpha-smooth muscle actin expression and myofibroblast differentiation via myocardin and serum response factor. *J. Biol. Chem.* 288, 33483–33493. doi: 10.1074/jbc.M113.504290

Abraham, D. J., and Varga, J. (2005). Scleroderma: from cell and molecular mechanisms to disease models. *Trends Immunol.* 26, 587–595. doi: 10.1016/j.it.2005.09.004

Akhter, S., Palumbo, K., dees, C., Bergmann, C., Venalis, P., Zerr, P., et al. (2012). Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. *Nat. Commun.* 3, 735. doi: 10.1038/ncomms1734

Arita, K., Kobayashi, A., Misawa, R., Shimizu, A., Nakata, T., et al. (2012). Role of bone marrow cells in the development of pulmonary fibrosis in a rat model of pancreatitis induced by a choline-deficient-ethionine-supplemented diet. *Biochem. Biophys. Res. Commun.* 420, 743–749. doi: 10.1016/j.bbrc.2012.03.060

Amara, N., Goven, D., Prost, F., Mulosay, R., Crestani, B., and Boczkowski, J. (2010). NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. *Thorax* 65, 733–738. doi: 10.1136/thx.2009.113456

Arcasoy, S. M., Christie, J. D., Pochettino, A., Rosengard, B. R., Blumenthal, N. P., Bavaria, J. J., et al. (2001). Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. *Chest* 120, 873–880. doi: 10.1378/chest.120.3.873

Armelyn, H. A. (1973). Pituitary extracts and steroid hormones in the control of 3T3 cell growth. *Proc. Natl. Acad. Sci. U.S.A.* 70, 2702–2706. doi: 10.1073/pnas.70.9.2702

Armulik, A., Genove, G., Mae, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., et al. (2010). Pericytes regulate the blood-brain barrier. *Nature* 468, 557–561. doi: 10.1038/nature09522

Arson, Y., Amital, H., Agmon-Levin, N., Alon, D., Sanchez-Castanon, M., Lopez-Hoyos, M., et al. (2011). Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. *Autoimmun. Rev.* 10, 490–494. doi: 10.1016/j.autrev.2011.02.002

Atanelishvili, L., Liang, J., Akter, T., Spyropoulos, D. B., Silver, R. M., and Bogatkevich, G. S. (2014). Thrombin increases lung fibroblast survival while promoting alveolar epithelial cell apoptosis via the endoplasmic reticulum stress marker, CCAAT enhancer-binding homologous protein. *Am. J. Respir. Cell Mol. Biol.* 50, 893–902. doi: 10.1165/rcmb.2013-0317OC

Barisic-Dujmovic, T., Boban, I., and Clark, S. H. (2010). Thrombin increases lung fibroblast survival while promoting alveolar epithelial cell apoptosis via the endoplasmic reticulum stress marker, CCAAT enhancer-binding homologous protein. *Am. J. Respir. Cell Mol. Biol.* 50, 893–902. doi: 10.1165/rcmb.2013-0317OC

www.frontiersin.org May 2014 Volume 5 Article 123 9
pulmonary fibrosis. *Cytokine* 24, 266–276. doi: 10.1016/j.cyto.2003.08.003

Gilbane, A. J., Denton, C. P., and Holmes, A. M. (2013). Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. *Arthritis Res. Ther.* 15, 215. doi: 10.1186/1741-7007-15-215

Glenisson, W., Castronovo, V., and Waltegry, D. (2007). Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation. *Biochim. Biophys. Acta* 1773, 1572–1582. doi: 10.1016/j.bbamcr.2007.05.016

Goldstein, R. H., and Polgar, P. (1982). The effect and interaction of bradykinin and prostaglandins on protein and collagen production by lung fibroblasts. *J. Biol. Chem.* 257, 8630–8633.

Gospodarowicz, D. (1974). Localisation of a fibroblast growth factor and its effect on collagen synthesis. *Nature* 249, 305–308. doi: 10.1038/249305a0

Hashimoto, N., Jin, H., Liu, T., Chensue, S. W., and Phan, S. H. (2004). Bone marrow-derived progenitor cells in pulmonary fibrosis. *J. Clin. Invest.* 113, 243–252. doi: 10.1172/JCI200418847

Hebbar, M., Peyrat, J. P., Horney, L., Hatron, P. Y., Hachulla, E., and Devulder, B. (2000). Increased concentrations of the circulating angiogenesis inhibitor in patients with systemic sclerosis. *Arthritis Rheum.* 43, 889–893. doi: 10.1002/1529-0131(200004)43:4<889::AID-ANR2>3.0.CO;2-5

Heljasvaara, R., Nyberg, P., Luostarinen, J., Parikka, M., Heikila, P., Rehn, M., et al. (2005). Generation of biologically active endostatin fragments from human collagen XVII by distinct matrix metalloproteinases. *Exp. Cell Res.* 307, 292–304. doi: 10.1016/j.yexcr.2005.03.021

Hemmatalaz, H., Rodrigues, H. M., Maurer, B., Brentano, F., Pileckyte, M., Distler, J., et al. (2011). The beta-arrestin pathway-selective type 1A angiotensin receptor (AT1A) agonist [Sar1Ile4Ile8]angiotensin II regulates a robust G protein-independent signaling network. *J. Biol. Chem.* 286, 19880–19891. doi: 10.1074/jbc.M111.233080

Khan, K., Xu, S., Nihytsana, V., Derrett-Smith, E., Abraham, D., Denton, C. P., et al. (2012). Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. *Ann. Rheum. Dis.* 71, 1235–1242. doi: 10.1136/annrheumdis-2011-200995

King, T. E. Jr., Tooez, J. A., Schwartz, M. I., Brown, K. R., and Cherniack, R. M. (2001). Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. *Am. J. Respir. Crit. Care Med.* 164, 1171–1181. doi: 10.1164/ajrccm.164.7.2003140

Kisseleva, T., Uchimani, H., Feirt, N., Quintana-Bustamante, O., Segovia, J. C., Schwabe, R. F., et al. (2006). Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. *J. Hepatol.* 45, 429–438. doi: 10.1016/j.jhep.2006.04.014

Kolb, M., Margetts, P. J., Galt, T., Sime, P. J., Xing, Z., Schmidt, M., et al. (2001). Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. *J. Respir. Crit. Care Med.* 163, 770–777. doi: 10.1164/ajrccm.163.3.2006084

Kolodsiick, J. E., Peters-Golden, M., Larios, J., Toews, G. B., Thannickal, V. J., and Moore, B. B. (2003). Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E prostaglandin receptor 2 signaling and cyclic adenosine monophosphate elevation. *J. Respir. Cell Mol. Biol.* 29, 537–544. doi: 10.1165/rcmb.2002-0243OC

Lee, P., Langevitz, P., Alderdice, C. A., Aubrey, M., Baer, P. A., Baron, M., et al. (1992). Mortality in systemic sclerosis (scleroderma). *Q. J. Med.* 85, 139–148.

Leof, E. B., Proper, J. A., Shipley, G. D., DiCorleto, P., and Moses, H. L. (1986). Induction of c-sis mRNA and activity similar to platelet-derived growth factor due to autocrine transforming growth factor beta signaling. *Mol. Endocrinol.* 23, 516–524. doi: 10.1109/molend.1986.1959689

Kalluri, R., and Zeisberg, M. (2006). Fibroblasts in cancer. *Nat. Rev. Cancer* 6, 392–401. doi: 10.1038/nrc1877

Kapoor, M., Liu, S., Shi-wen, X., Huh, K., McCann, M., Denton, C. P., et al. (2008). GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism. *J. Clin. Invest.* 118, 3279–3290. doi: 10.1172/JCI33381R1

Kavian, N., Servettaz, A., Weill, B., and Batteux, F. (2012). New insights into the role of transforming growth factor-beta family in fibrosis. *Open Rheumatol. J.* 6, 96–102. doi: 10.2174/1874312901206010096

Kawelke, N., Vasel, M., Sens, C., Au, A., Dooley, S., and Nakchbandi, J. A. (2011). Fibronectin protects from excessive liver fibrosis by modulating the availability of and responsiveness to stellate cells to active TGF-beta. *PLoS ONE* 6:e28181. doi: 10.1371/journal.pone.0028181

Keech, J. L., Khosla, J., Maddox, R. T., Palmer, J. R., Turner, R. B., and Sibley, R. H. (2002). The effect and interaction of bradykinin and prostaglandins on protein and collagen production by lung fibroblasts. *J. Biol. Chem.* 275, 8630–8633.

Kajihara, I., Jinnin, M., Honda, N., Makino, K., Makino, T., Masuguchi, S., et al. (2013). Scleroderma dermal fibroblasts overexpress vascular endothelial growth factor due to autocrine transforming growth factor beta signaling. *Mol. Rheumatol.* 23, 516–524. doi: 10.1109/molend.1986.1959689

Kolodsiick, J. E., Peters-Golden, M., Larios, J., Toews, G. B., Thannickal, V. J., and Moore, B. B. (2003). Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E prostaglandin receptor 2 signaling and cyclic adenosine monophosphate elevation. *J. Respir. Cell Mol. Biol.* 29, 537–544. doi: 10.1165/rcmb.2002-0243OC

Lee, P., Langevitz, P., Alderdice, C. A., Aubrey, M., Baer, P. A., Baron, M., et al. (1992). Mortality in systemic sclerosis (scleroderma). *Q. J. Med.* 85, 139–148.

Leof, E. B., Proper, J. A., Goustin, A. S., Shipley, G. D., DiCorleto, P. E., and Moses, H. L. (1986). Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. *Proc. Natl. Acad. Sci. U.S.A.* 83, 2453–2457. doi: 10.1073/pnas.83.8.2453

Li, M., Riddle, S. R., Frid, M. G., El-Kamhi, K. C., McKinsey, T. A., Sokol, R. J., et al. (2011). Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. *J. Immunol.* 187, 2711–2722. doi: 10.4049/jimmunol.1100479

Liu, J., Wang, Y., Pan, Q., Su, Y., Zhang, Z., Han, J., et al. (2012). Wnt/beta-catenin pathway forms a negative feedback loop during TGF-beta1 induced human normal skin fibroblast-to-myofibroblast transition. *J. Dermatol. Sci.* 65, 38–49. doi: 10.1016/j.jdermsci.2011.09.012
Paulsson, Y., Hammacher, A., Heldin, C. H., and Westermark, B. (1987). Possible positive autocrine feedback in the prereplicative phase of human fibroblasts. Nature 328, 715–717. doi:10.1038/328715a0
Pearson, C. A., Pearson, D., Shibahara, S., Hofsteenge, J., and Chiquet-Ehrismann, R. (1988). Tenascin: cDNA cloning and induction by TGF-beta. EMBO J. 7, 2977–2982.
Peckovský, D. V., Hackett, T. L., An, S. S., Shaheen, F., Murray, L. A., and Knight, D. A. (2010). Human lung parenchyma but not proximal bronchi produces fibroblasts with enhanced TGF-beta signaling and alpha-SMA expression. Am. J. Respir. Cell Mol. Biol. 43, 641–651. doi:10.1165/rcmb.2009-0318OC
Piera-Velazquez, S., Li, Z., and Jimenez, S. A. (2011). Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am. J. Pathol. 179, 1074–1080. doi:10.1016/j.ajpath.2011.06.001
Pilling, D., and Gorner, R. H. (2012). Differentiation of circulating monocytes into fibroblast-like cells. Methods Mol. Biol. 904, 191–206. doi:10.1007/978-1-61779-943-1_16
Potter, J. J., Liu, X., Koteish, A., and Mezey, E. (2013). 1,25-dihydroxyvitamin D3 and its nuclear receptor repress human alpah (1) collagen expression and type I collagen formation. Liver Int. 33, 677–686. doi:10.1111/liv.12122
Qian, J., Niu, M., Zhai, X., Zhou, Q., and Zhou, Y. (2012). beta-Catenin pathway is required for TGF-beta1 inhibition of PPARgamma expression in cultured hepatic stellate cells. Pharmacol. Res. 66, 219–225. doi:10.1016/j.phrs.2012.06.003
Quan, T. E., Cowper, S., Wu, S. P., Bockenstedt, L. K., and Bucala, R. (2004). Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int. J. Biochem. Cell Biol. 36, 598–606. doi:10.1016/j.biocel.2003.10.005
Ramirez, A. M., Wongtrakool, C., Welch, T., Steinmeyer, A., Zugel, U., and Roman, J. (2010). Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J. Steroid Biochem. Mol. Biol. 118, 142–150. doi:10.1016/j.jsbmb.2009.11.004
Richter, A. G., McKeown, S., Rathinam, S., Harper, L., Rajesh, P., McAuley, D. F., et al. (2009). Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 64, 156–161. doi:10.1136/thx.2008.102814
Rios Fernandez, R., Fernandez Roldan, C., Callejas Rubio, J. L., and Ortego Centeno, N. (2010). Vitamin D deficiency in a cohort of patients with systemic sclerosis from the south of Spain. J. Rheumatol. 37, 1355; author reply 1356. doi:10.3899/jrheum.091143
Rock, J. R., Barkauskas, C. E., Cronce, M. J., Xue, Y., Harris, J. R., Liang, J., et al. (2011). Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl. Acad. Sci. U.S.A. 108, E1475–E1483. doi:10.1073/pnas.1117988108
Rosenkranz, S. (2004). TGF-beta and angiostatin in cardiac remodeling. Cardiovasc. Res. 63, 423–432. doi:10.1016/j.cardiores.2004.04.030
Ruz, X. D., Alakar, L. R., Yamaguchi, Y., Su, Y., Larregina, A. T., Pilewski, J. M., et al. (2012). Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis. PLoS ONE 7:e43049. doi:10.1371/journal.pone.0043049
Saltzman, L. E., Moss, J., Berg, R. A., Hom, B., and Crystal, R. G. (1982). Modulation of collagen production by fibroblasts. Effects of chronic exposure to agonists that increase intracellular cyclic AMP. Biochem. J. 204, 25–30.
Sanada, S., Hakuno, D., Higgins, L. J., Schreiter, E. R., McKenzie, A. N., and Lee, R. T. (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538–1549. doi:10.1172/JCI30634
Santos, V. N., Leite-Mor, M. M., Kondo, M., Martins, J. R., Nader, H., Lanzoní, V. P., et al. (2005). Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz. J. Med. Biol. Res. 38, 747–753. doi:10.1590/S0100-879X2005000500012
Savinko, T., Matikainen, S., Saarialho-Kere, U., Lehto, M., Wang, G., Lehtimaki, S., et al. (2012). IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J. Invest. Dermatol. 132, 1392–1400. doi:10.1038/jid.2011.446
Schnapp, L. M., Hatch, N., Klimanskaya, D. M., Sheppard, D., and Pytel, R. A. (1998). The human integrin alpha 8 beta 1 functions as a receptor for tenasin, fibronectin, and vitronectin. J. Biol. Chem. 273, 23196–23202. doi:10.1074/jbc.270.39.23196
Schirmpf, C., Xin, C., Camphanholle, G., Gill, S. E., Stairopoulou, W., Lin, S. L., et al. (2012). Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J. Am. Soc. Nephrol. 23, 868–883. doi:10.1681/ASN.2011080851
Scotton, C. J., and Chambers, R. C. (2007). Molecular targets in pulmonary fibrosis: the myofibroblast in focus. *Chest* 132, 1311–1321. doi: 10.1378/chest.06-2568

Seki, E., De Minicis, S., Osterreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., et al. (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat. Med.* 13, 1324–1332. doi: 10.1038/nm1663

Slominski, A., Janjetovic, Z., Tuckey, R. C., Nguyen, M. N., Bhattacharya, K. G., Wang, J., et al. (2013). 205-hydroxyvitamin D3, nonalcalcemic product of CYP11A1 action on vitamin D3, exhibits potent antiinflammatory activity in vivo. *J. Clin. Endocrinol. Metabol.* 98, E298–E303. doi: 10.1210/jc.2012-3074

Soma, Y., and Grotendorst, G. R. (1989). TGF-beta stimulates primary human skin fibroblast DNA synthesis via an autocrine production of PDGF-related peptides. *J. Cell. Physiol.* 140, 246–253. doi: 10.1002/jcp.1041400209

Sonnylal, S., Shi-Wen, X., Leoni, P., Naff, K., Van Pelt, C. S., Nakamura, H., et al. (2010). Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. *Arthritis Rheum.* 62, 1523–1532. doi: 10.1002/art.27382

Stenmark, K. R., Fagan, K. A., and Frid, M. G. (2006). Hypoxia-induced pulmonary remodeling: cellular and molecular mechanisms. *Circ. Res.* 99, 675–691. doi: 10.1161/01.RES.0000243584.45145.3f

Stewart, G. A., Hoyne, G. E., Ahmad, S. A., Jarman, E., Wallace, W. A., Harrison, D. J., et al. (2003). Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. *Pathol. J.* 498, 489–495. doi: 10.1002/path.1295

Stratton, R., Rajkumar, V., Ponticos, M., Nichols, B., Shiwon, X., Black, C. M., et al. (2002). Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. *FASEB J.* 16, 1949–1951. doi: 10.1096/fj.02-2040fje

Strehlow, D., and Korn, J. H. (1998). Biology of the scleroderma fibroblast. *Curr. Opin. Rheumatol.* 10, 572–578. doi: 10.1097/00022281-199811000-00011

Sunmi, M., Sato, H., Kagoshii, K., Ishikawa, H., and Sekizawa, K. (2005). Increased serum levels of endostatin in patients with idiopathic pulmonary fibrosis. *J. Clin. Lab. Anal.* 19, 146–149. doi: 10.1002/jcla.20069

Tjin Tham Sjin, R. M., Satchi-Fainaro, R., Birsner, A. E., Ramanujam, V. M., Torres, M. A., Eldar-Finkelman, H., Krebs, E. G., and Moon, R. T. (1999). Increased serum levels of endostatin in patients with idiopathic pulmonary fibrosis: the myofibroblast in focus. *Chest* 116, 140–145. doi: 10.1378/chest.116.1.140

Yu, W. H., and Woessner, J. F. Jr. (2000). TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. *J. Rheumatol.* 27, 13226–13232. doi: 10.1067/mar.2000.115351

Vacca, A., Cermier, C., Piras, M., Mathieu, A., Kahan, A., and Allanore, Y. (2009). Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. *J. Rheumatol.* 36, 1924–1929. doi: 10.3899/jrheum.081287

Wang, L., Li, Y. L., Zhang, C. C., Cui, W., Wang, X., Xia, Y., et al. (2014). Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. *Cardiovasc. Res.* 101, 383–392. doi: 10.1093/cvr/cet258

Wang, X. M., Zhang, Y., Kim, H. J., Zhou, Z., Feghali-Bostwick, C. A., Liu, F., et al. (2006b). Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. *J. Exp. Med.* 203, 2895–2906. doi: 10.1084/jem.20061536

Wei, J., Bhattacharyya, S., Jain, M., and Varga, J. (2012). Regulation of matrix remodeling by peroxisome proliferator-activated receptor-gamma: a novel link between metabolism and fibrogenesis. *Open Rheumatol. J.* 6, 103–115. doi: 10.2174/1874312901206010103

Wynn, T. A. (2003). IL-13 effector functions. *Annu. Rev. Immunol.* 21, 425–456. doi: 10.1146/annurev.immunol.21.120601.141142

Yamaguchi, Y., Mann, D. M., and Ruoslahti, E. (1999). Negative regulation of transforming growth factor-beta by the proteoglycan decorin. *Nature* 346, 281–284. doi: 10.1038/346281a0

Yamaguchi, Y., Takahara, T., Chambers, R. A., Veraldi, K. L., Larregina, A. T., and Feghali-Bostwick, C. A. (2012). A peptide derived from endostatin ameliorates organ fibrosis. *Sci. Trans. Med.* 4, 136ea171. doi: 10.1126/scitranslmed.3003421

Yasuo, H., Larregina, A. T., Yamaguchi, Y., and Feghali-Bostwick, C. A. (2008). Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins. *Open Rheumatol. J.* 2, 17–22. doi: 10.2174/1874312900802010017

Yu, W. H., and Yu, S., Meng, Q., Brew, K., and Woessner, J. F. Jr. (2000). Heparan sulfate proteoglycans as extracellular molecular docking molecules for matrixylisin (matrix metalloproteinase 7). *J. Biol. Chem.* 275, 4183–4191. doi: 10.1074/jbc.275.6.4183

Yusuf, M., Siddiqui, S., Khandaker, S., and Sultana, F. (2011). Altered monocyt and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. *J. Biomed. Sci.* 18, 1427–1437. doi: 10.1002/jbc.M000907200

Yu, W. H., Yu, S., Meng, Q., Brew, K., and Woessner, J. F. Jr. (2000). TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. *J. Biol. Chem.* 275, 31226–31232. doi: 10.1074/jb.000907200

Zeijsberg, M., Bonner, G., Maeshima, Y., Colorado, P., Muller, G. A., Strutz, F., et al. (2011). Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. *Am. J. Pathol.* 159, 1313–1321. doi: 10.1016/S0002-9440(10)62518-7

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Received:** 19 March 2014; **accepted:** 09 May 2014; **published online:** 27 May 2014. Citation: Kendall RT and Feghali-Bostwick CA (2014) Fibroblasts in fibrosis: novel roles and mediators. *Front. Pharmacol.* 5:123. doi: 10.3389/fphar.2014.00123

This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology. Copyright © 2014 Kendall and Feghali-Bostwick. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.